Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells

Journal of RNAi and Gene Silencing

Volumn 10, Issue 2, 2015, Pages 500-506

  Esposito, Carla Lucia ^a   Catuogno, Silvia ^a   de Franciscis, Vittorio ^a  

^a CNR   (Italy)

Author keywords

Aptamer; Cancer; microRNA; siRNA; Targeted delivery

Indexed keywords

APTAMER; MICRORNA; SMALL INTERFERING RNA;

BINDING AFFINITY; CANCER CELL; CANCER GENE THERAPY; CANCER THERAPY; CONJUGATION; HUMAN; RNA BINDING; RNA INTERFERENCE; SHORT SURVEY;

EID: 84925047153     PISSN: 17470854     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (48)

1. Amarzguioui M and Rossi JJ. 2008. Principles of Dicer substrate (D-siRNA) design and function. Methods Mol Biol, 442, 3-10.
2. Bagalkot V, Farokhzad OC, Langer R, Jon S. 2006. Anaptamer doxorubicin physical conjugateas a novel targeted drug-delivery platform. Angew Chem Int Ed Engl, 45, 8149-8152.
3. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. 2009. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol, 86, 151-164.
4. Berezhnoy A, Castro I, Levay A, Malek TR, Gilboa E. 2014. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J Clin Invest, 124, 188-197.
5. Bora RS, Gupta D, Mukkur TK, Saini KS. 2012. RNA interference therapeutics for cancer: Challenges and opportunities (Review). Mol Med Rep, 6, 9-15.
6. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. 2010. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer, 17, F19-36.
7. Cerchia L and de Franciscis V. 2010. Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol, 28, 517-525.
8. Cerchia L, Esposito CL, Camorani S et al. 2012. Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther, 20, 2291-2303.
9. Chen CH, Dellamaggiore KR, Ouellette CP et al. 2008. Aptamerbased endocytosis of a lysosomal enzyme. Proc Natl Acad Sci USA, 105, 15908-15913.
10. Chu TC, Marks J W 3rd, Lavery LA et al. 2006a. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res, 66, 5989-5992.
11. Chu TC, Twu KY, Ellington, AD, Levy M. 2006b. Aptamer mediated siRNA delivery. Nucleic Acids Res, 34, e73.
12. Dai F, Zhang Y, Zhu X, Shan N, Chen Y. 2012. Anticancer role of MUC1aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation. Target Oncol, 7, 217-225.
13. Dassie JP, Liu XY, Thomas GS et al. 2009. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol, 27, 839-849.
14. Di Leva G, Garofalo M, Croce CM. 2013. MicroRNAs in cancer. Annu Rev Pathol, 14, 287-314.
15. Esposito CL, Catuogno S, de Franciscis V, Cerchia L. 2011. New insight into clinical development of nucleic acid aptamers. Discov Med, 11, 487-496.
16. Esposito CL, Cerchia L, Catuogno S et al. 2014. Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Mol Ther 22, 1151-1163.
17. Farokhzad OC, Cheng J, Teply BA et al. 2006. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA, 103, 6315-6320.
18. Hao Z, Fan W, Hao J et al. 2014. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo. Drug Deliv, 3, 1-8.
19. Herrmann A, Priceman SJ, Kujawski MJ et al. 2014. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. Clin Invest, 124, 2977-2987.
20. Hicke BJ, Stephens AW, Gould T et al. 2006. Tumor targeting by an aptamer. J Nucl Med, 47, 668-678.
21. Kasinski AL and Slack FJ. 2011. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nature Reviews Cancer 11, 849-864
22. Kay MA. 2011. State-of-the-art gene-based therapies: the road ahead. Nature Reviews Genetics, 12, 316-328.
23. Kim JK, Choi KJ, Lee M, Jo MH, Kim S. 2012. Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials, 33, 207-217.
24. Kufe DW. 2009. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer, 9, 874-885.
25. Lai WY, Wang WY, Chang YC, Chang CJ, Yang PC, Peck K. 2014. Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras. Biomaterials, 35, 2905-2914.
26. Li L, Hou J, Liu X et al. 2014. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials. 2014, 35, 3840-3850.
27. Liu N, Zhou C, Zhao J, Chen Y. 2012. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamerlet-7i chimera. Cancer Invest, 30, 577-82.
28. Lupold SE, Hicke BJ, Lin Y, Coffey DS. 2002. Identification and characterization of nuclease stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res, 62, 4029-4033.
29. McNamara JO 2nd, Andrechek ER, Wang Y et al. 2006. Cell typespecific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol, 24, 1005-1015.
30. Ni X, Zhang Y, Ribas J et al. 2011. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest, 121, 2383-2390.
31. Pastor F, Kolonias D, Giangrande PH, Gilboa E. 2010. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decoy. Nature, 465, 227- 230.
32. Rand TA, Petersen S, Du F, Wang X. 2005. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell, 123, 621-629.
33. Rao DD, Wang Z, Senzer N, Nemunaitis J. 2013. RNA interference and personalized cancer therapy. Discov Med, 15, 101-110.
34. Shukla S, Sumaria CS and Pradeepkumar PI. 2010. Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. ChemMedChem, 5, 328-349.
35. Tan Y, Shi YS, Wu XD et al. 2013. DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro. Acta Pharmacol Sin, 34, 1491-1498.
36. Thiel KW, Hernandez L, Dassie JP et al. 2012. Delivery of chemosensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res, 40, 6319-6337.
37. Toniatti C, Jones P, Graham H, Pagliara B, Draetta G. 2014. Oncology drug discovery: planning a turn around. Cancer Discov, 4, 397-404.
38. Tuek C and Gold L. 1990 Systematic Evolution of Ligands by Exponential Enrichment RNA Ligands to Bacteriophage T4 Polymerase. Science, 249, 505-510.
39. Uchino K, Ochiya T, Takeshita F. 2013. RNAi therapeutics and applications of microRNAs in cancer treatment. Jpn J Clin Oncol, 43, 596-607.
40. Yoo H, Jung H, Kim SA, Mok H. 2014. Multivalent comb-type aptamer-siRNA conjugates for efficient and selective intracellular delivery. Chem Commun (Camb), 50, 6765-6767.
41. Wang J, Sefah K, Altman MB et al. 2013. Aptamer-Conjugated Nanorods for Targeted Photothermal Therapy of Prostate Cancer Stem Cells. Chem Asian J, 8, 2417-2422.
42. Wu SY, Lopez-Berestein G, Calin GA, Sood AK. 2014. RNAi Therapies: Drugging the Undruggable. Sci. Transl. Med, 6, 240ps7.
43. Wu X, Ding B, Gao J et al. 2011. Second-generation aptamerconjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomedicine, 6, 1747-1756.
44. Wullner U, Neef I, Eller A, Kleines M, Tur MK, Barth S. 2008. Cellspecific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets, 8, 554-565.
45. Zhang X, Liang H, Tan Y, Wu X, Li S, Shi Y. 2014. A U87- EGFRvIII cell-specific aptamer mediates small interfering RNA delivery Biomed Rep, 2, 495-499.
46. Zhou J and Rossi JJ. 2010. Aptamer-targeted cell-specific RNA interference. Silence, 1, 4.
47. Zhou J, Shum KT, Burnett JC, Rossi JJ. 2013a. Nanoparticle- Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel), 6, 85-107.
48. Zhou J, Neff CP, Swiderski P et al. 2013b. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther, 21, 192-200.